SeekingAlpha · Aug 13, 2026
MiNK Therapeutics, Inc. (INKT) Presents at 2026 Military Health System Research Symposium - Slideshow
2026-08-13. The following slide deck was published by MiNK Therapeutics, Inc.
IN
NASDAQ · INKT
MiNK Therapeutics, Inc.
Healthcare · Biotechnology
$11.64
Down-$0.12 (-1.03%)
Updated Sep 8, 2026, 4:35 PM
SID Score
4.0/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 58.3M
- P/E ratio
- -0.01
- Dividend yield
- 0.00%
- 52-week range
- $8.48 – $16.98
- Volume
- 5.87K
- Avg. volume
- 28.08K
Price performance
INKT price history
1M range · 20 trading sessions · Daily adjusted prices
INKT closed at $11.64 after 20 trading sessions, up 6.30% for the selected period.
- Last close
- $11.64
- Period change
- +6.30%
- Period low
- $10.95
- Period high
- $12.20
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 4, 2026 | $11.16 | $11.64 | $11.16 | $11.64 | 5.87K |
| Sep 3, 2026 | $11.08 | $11.54 | $11.08 | $11.23 | 3.21K |
| Sep 2, 2026 | $11.00 | $11.42 | $10.82 | $11.33 | 8.26K |
| Sep 1, 2026 | $11.02 | $11.35 | $10.95 | $10.95 | 2.24K |
| Aug 31, 2026 | $11.51 | $11.75 | $10.95 | $11.09 | 11.88K |
| Aug 28, 2026 | $11.325 | $11.45 | $11.06 | $11.4282 | 6.95K |
| Aug 27, 2026 | $11.60 | $11.7995 | $11.455 | $11.68 | 4.7K |
| Aug 26, 2026 | $11.29 | $11.79 | $11.29 | $11.79 | 9.03K |
| Aug 25, 2026 | $11.26 | $11.80 | $11.04 | $11.38 | 9.35K |
| Aug 24, 2026 | $12.24 | $12.24 | $11.51 | $11.82 | 8.12K |
| Aug 21, 2026 | $11.64 | $12.20 | $11.22 | $12.20 | 11.78K |
| Aug 20, 2026 | $11.10 | $11.70 | $10.98 | $11.62 | 11.35K |
| Aug 19, 2026 | $11.84 | $12.0899 | $11.00 | $11.13 | 14.46K |
| Aug 18, 2026 | $11.01 | $12.00 | $11.01 | $12.00 | 10.59K |
| Aug 17, 2026 | $11.15 | $11.49 | $11.0612 | $11.22 | 7.83K |
| Aug 14, 2026 | $11.10 | $11.50 | $10.9501 | $11.27 | 6.79K |
| Aug 13, 2026 | $11.29 | $11.32 | $10.82 | $11.00 | 8.61K |
| Aug 12, 2026 | $11.06 | $11.60 | $11.06 | $11.36 | 4.72K |
| Aug 11, 2026 | $10.95 | $11.5587 | $10.95 | $11.23 | 5.92K |
| Aug 10, 2026 | $10.96 | $10.96 | $10.80 | $10.95 | 5.14K |
Latest INKT news
The latest Smart Investors Daily articles mentioning INKT.
Stock researchCompany · Overview
INKT research
Overview
Company profile and research snapshot.
Company profile
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $35.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| May 18, 2026 | HC Wainwright & Co. | Buy | — |
| Apr 1, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 15, 2025 | HC Wainwright & Co. | Buy | — |
| Jul 15, 2025 | HC Wainwright & Co. | Neutral | — |
| Jul 14, 2025 | William Blair | Market Perform | — |
News briefing
No generated briefing is available yet.
SeekingAlpha · Aug 13, 2026
MiNK Therapeutics, Inc. (INKT) Q2 2026 Earnings Call Transcript
MiNK Therapeutics, Inc. (INKT) Q2 2026 Earnings Call August 13, 2026 8:30 AM EDTCompany ParticipantsJennifer Buell - Co-Founder, President, CEO &...
Benzinga · Aug 13, 2026
MiNK Therapeutics Q2 2026 Earnings Call: Complete Transcript
MiNK Therapeutics (NASDAQ:INKT) held its second-quarter earnings conference call on Thursday. Below is the complete transcript from the call. This transcript is brought to you by Benzinga APIs. For real-time access to
Benzinga · Aug 13, 2026
MiNK Therapeutics Q2 EPS $(0.62) Misses $(0.60) Estimate
MiNK Therapeutics (NASDAQ:INKT) reported quarterly losses of $(0.62) per share which missed the analyst consensus estimate of $(0.60) by 3.33 percent. This is a 41.51 percent increase over losses of $(1.06) per share
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
